These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26823647)

  • 1. Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya.
    Pintye J; Langat A; Singa B; Kinuthia J; Odeny B; Katana A; Nganga L; John-Stewart G; McGrath CJ
    Infect Dis Obstet Gynecol; 2015; 2015():276851. PubMed ID: 26823647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.
    Siberry GK; Williams PL; Mendez H; Seage GR; Jacobson DL; Hazra R; Rich KC; Griner R; Tassiopoulos K; Kacanek D; Mofenson LM; Miller T; DiMeglio LA; Watts DH;
    AIDS; 2012 Jun; 26(9):1151-9. PubMed ID: 22382151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.
    Nachega JB; Uthman OA; Mofenson LM; Anderson JR; Kanters S; Renaud F; Ford N; Essajee S; Doherty MC; Mills EJ
    J Acquir Immune Defic Syndr; 2017 Sep; 76(1):1-12. PubMed ID: 28291053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of tenofovir during pregnancy: early growth outcomes and hematologic side effects in HIV-exposed uninfected infants.
    Seidel V; Weizsäcker K; Henrich W; Rancourt RC; Bührer C; Krüger R; Feiterna-Sperling C
    Eur J Pediatr; 2020 Jan; 179(1):99-109. PubMed ID: 31659467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower birth weight-for-age and length-for-age z-scores in infants with in-utero HIV and ART exposure: a prospective study in Cape Town, South Africa.
    Nyemba DC; Kalk E; Madlala HP; Malaba TR; Slogrove AL; Davies MA; Boulle A; Myer L; Powis KM
    BMC Pregnancy Childbirth; 2021 May; 21(1):354. PubMed ID: 33947351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir exposure in utero and linear growth in HIV-exposed, uninfected infants.
    M le Roux S; Jao J; Brittain K; Phillips TK; Olatunbosun S; Ronan A; Zerbe A; Abrams EJ; Myer L
    AIDS; 2017 Jan; 31(1):97-104. PubMed ID: 27898591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher prevalence of stunting and poor growth outcomes in HIV-exposed uninfected than HIV-unexposed infants in Kenya.
    Neary J; Langat A; Singa B; Kinuthia J; Itindi J; Nyaboe E; Ng'anga' LW; Katana A; John-Stewart GC; McGrath CJ
    AIDS; 2022 Mar; 36(4):605-610. PubMed ID: 34750290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
    Gibb DM; Kizito H; Russell EC; Chidziva E; Zalwango E; Nalumenya R; Spyer M; Tumukunde D; Nathoo K; Munderi P; Kyomugisha H; Hakim J; Grosskurth H; Gilks CF; Walker AS; Musoke P;
    PLoS Med; 2012; 9(5):e1001217. PubMed ID: 22615543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth trajectories of breastfed HIV-exposed uninfected and HIV-unexposed children under conditions of universal maternal antiretroviral therapy: a prospective study.
    le Roux SM; Abrams EJ; Donald KA; Brittain K; Phillips TK; Nguyen KK; Zerbe A; Kroon M; Myer L
    Lancet Child Adolesc Health; 2019 Apr; 3(4):234-244. PubMed ID: 30773459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.
    Himes SK; Wu JW; Jacobson DL; Tassiopoulos K; Hazra R; Kacanek D; Van Dyke RB; Rich KC; Siberry GK; Huestis MA;
    Pediatr Infect Dis J; 2015 Aug; 34(8):851-7. PubMed ID: 25961889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth and Neurodevelopment Outcomes in HIV-, Tenofovir-, and Efavirenz-Exposed Breastfed Infants in the PMTCT Option B+ Program in Malawi.
    Kapito-Tembo AP; Bauleni A; Wesevich A; Ongubo D; Hosseinipour MC; Dube Q; Mwale P; Corbett A; Mwapasa V; Phiri S
    J Acquir Immune Defic Syndr; 2021 Jan; 86(1):81-90. PubMed ID: 33027153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.
    Mofenson LM; Baggaley RC; Mameletzis I
    AIDS; 2017 Jan; 31(2):213-232. PubMed ID: 27831952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
    Mugo NR; Hong T; Celum C; Donnell D; Bukusi EA; John-Stewart G; Wangisi J; Were E; Heffron R; Matthews LT; Morrison S; Ngure K; Baeten JM;
    JAMA; 2014 Jul 23-30; 312(4):362-71. PubMed ID: 25038355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal Tenofovir Disoproxil Fumarate Use During Pregnancy Is Not Associated With Adverse Perinatal Outcomes Among HIV-infected East African Women: A Prospective Study.
    Pintye J; Baeten JM; Celum C; Mugo N; Ngure K; Were E; Bukusi EA; John-Stewart G; Heffron RA
    J Infect Dis; 2017 Dec; 216(12):1561-1568. PubMed ID: 29040666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth of infants born to HIV-infected women in South Africa according to maternal and infant characteristics.
    Venkatesh KK; Lurie MN; Triche EW; De Bruyn G; Harwell JI; McGarvey ST; Gray GE
    Trop Med Int Health; 2010 Nov; 15(11):1364-74. PubMed ID: 20955499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perinatal outcomes following maternal pre-exposure prophylaxis (PrEP) use during pregnancy: results from a large PrEP implementation program in Kenya.
    Dettinger JC; Kinuthia J; Pintye J; Abuna F; Begnel E; Mugwanya K; Sila J; Lagat H; Baeten JM; John-Stewart G
    J Int AIDS Soc; 2019 Sep; 22(9):e25378. PubMed ID: 31498563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
    Chetty T; Thorne C; Coutsoudis A
    PLoS One; 2018; 13(2):e0192805. PubMed ID: 29470508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
    Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR;
    J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth patterns of infants with in- utero HIV and ARV exposure in Cape Town, South Africa and Lusaka, Zambia.
    Nyemba DC; Kalk E; Vinikoor MJ; Madlala HP; Mubiana-Mbewe M; Mzumara M; Moore CB; Slogrove AL; Boulle A; Davies MA; Myer L; Powis K
    BMC Public Health; 2022 Jan; 22(1):55. PubMed ID: 35000577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.
    Viganò A; Mora S; Giacomet V; Stucchi S; Manfredini V; Gabiano C; Salvini F; Cellini M; Tamburrini E; Puzzovio M; Zuccotti GV
    Antivir Ther; 2011; 16(8):1259-66. PubMed ID: 22155907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.